4.7 Article

Renal impairment and outcomes in heart failure - Systematic review and meta-analysis

Journal

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 47, Issue 10, Pages 1987-1996

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2005.11.084

Keywords

-

Funding

  1. NIGMS NIH HHS [GM07205] Funding Source: Medline

Ask authors/readers for more resources

OBJECTIVES We estimated the prevalence of renal impairment in heart failure (HF) patients and the magnitude of associated mortality risk using a systematic review of published studies. BACKGROUND Renal impairment in HF patients is associated with excess mortality, although precise risk estimates are unclear. METHODS A systematic search of MEDLINE (through May 2005) identified 16 studies characterizing the association between renal impairment and mortality in 80,098 hospitalized and non-hospitalized HF patients. All-cause mortality risks associated with any renal impairment (creatinine > 1.0 mg/dl, creatinine clearance [CrCl] or estimated glomerular filtration rate [eGFR] < 90 ml/min, or cystatin-C > 1.03 mg/dl) and moderate to severe impairment (creatinine >= 1.5, CrCl or eGFR < 53, or cystatin-C >= 1.56) were estimated using fixed-effects meta-analysis. RESULTS A total of 63% of patients had any renal impairment, and 29% had moderate to severe impairment. After follow-up >= 1 year, 38% of patients with any renal impairment and 51% with moderate to severe impairment died versus 24% without impairment. Adjusted all-cause mortality was increased for patients with any impairment (hazard ratio [HR] = 1.56; 95% confidence interval [CI] 1.53 to 1.60, p < 0.001) and moderate to severe impairment (HR = 2.31; 95% CI 2.18 to 2.44, p < 0.001). Mortality worsened incrementally across the range of renal function, with 15% (95% CI 14% to 17%) increased risk for every 0.5 mg/dl increase in creatinine and 7% (95% CI 4% to 10%) increased risk for every 10 ml/min decrease in eGFR. CONCLUSIONS Renal impairment is common among HF patients and confers excess mortality. Renal function should be considered in risk stratification and evaluation of therapeutic strategies for HF patients. (J Am Coll Cardiol 2006;47:1987-96) (c) 2006 by the American College of Cardiology Foundation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available